A detailed history of Geode Capital Management, LLC transactions in Silverback Therapeutics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 1,234,805 shares of SBTX stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,234,805
Previous 1,195,878 3.26%
Holding current value
$0
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
N/A
38,927 Added 3.26%
1,234,805 $0
Q2 2024

Aug 09, 2024

BUY
N/A
319,207 Added 36.41%
1,195,878 $0
Q1 2024

May 13, 2024

BUY
N/A
11,802 Added 1.36%
876,671 $0
Q4 2023

Feb 13, 2024

BUY
N/A
61,528 Added 7.66%
864,869 $0
Q3 2023

Nov 13, 2023

BUY
N/A
149,746 Added 22.91%
803,341 $0
Q2 2023

Aug 11, 2023

BUY
N/A
249,991 Added 61.94%
653,595 $0
Q1 2023

May 15, 2023

BUY
N/A
71,408 Added 21.5%
403,604 $0
Q4 2022

Feb 13, 2023

BUY
$0.0 - $6.07 $0 - $654,418
107,812 Added 48.05%
332,196 $2.83 Million
Q3 2022

Nov 14, 2022

BUY
$3.91 - $5.52 $2,862 - $4,040
732 Added 0.33%
224,384 $1.18 Million
Q2 2022

Aug 12, 2022

SELL
$2.9 - $4.44 $403,065 - $617,106
-138,988 Reduced 38.33%
223,652 $948,000
Q1 2022

May 13, 2022

SELL
$3.51 - $6.74 $103,446 - $198,641
-29,472 Reduced 7.52%
362,640 $1.27 Million
Q4 2021

Feb 11, 2022

BUY
$6.03 - $11.67 $1.25 Million - $2.42 Million
207,000 Added 111.82%
392,112 $2.61 Million
Q3 2021

Nov 12, 2021

SELL
$9.98 - $35.22 $355,048 - $1.25 Million
-35,576 Reduced 16.12%
185,112 $1.85 Million
Q2 2021

Aug 13, 2021

BUY
$24.71 - $44.28 $51,075 - $91,526
2,067 Added 0.95%
220,688 $6.82 Million
Q1 2021

May 12, 2021

BUY
$37.62 - $60.41 $7.5 Million - $12 Million
199,391 Added 1036.87%
218,621 $9.54 Million
Q4 2020

Feb 12, 2021

BUY
$25.0 - $46.34 $480,750 - $891,118
19,230 New
19,230 $891,000

Others Institutions Holding SBTX

About Silverback Therapeutics, Inc.


  • Ticker SBTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,473,800
  • Description
  • Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverba...
More about SBTX
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.